Bank of America Upgrades BioCryst Pharmaceuticals To Buy

Bank of America upgraded

from Neutral to Buy. The price target for BioCryst Pharmaceuticals has been raised from $12.00 to $19.00. BioCryst Pharmaceuticals shares have gained 10.75 percent over the past 52 weeks, while the S&P 500 index has surged 4.27 percent in the same period. BioCryst Pharmaceuticals' shares closed at $14.42 yesterday.